

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SHANGHAI JUNSHI BIOSCIENCES CO., LTD.*

上海君實生物醫藥科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1877)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Reference is made to the “Shanghai Junshi Biosciences Co., Ltd.* Announcement on Election of Chairman of the Board of Directors, Vice Chairman of the Board of Directors, Members of Special Committees under the Board of Directors, Chairman of the Board of Supervisors and Appointment of Senior Management Personnel” (《上海君實生物醫藥科技股份有限公司關於選舉董事長、副董事長、董事會專門委員會委員、監事會主席及聘任高級管理人員的公告》) published by Shanghai Junshi Biosciences Co., Ltd.* on the website of the Shanghai Stock Exchange, which is for reference purpose only.

By order of the Board
Shanghai Junshi Biosciences Co., Ltd.*
Mr. Xiong Jun
Chairman

Shanghai, the PRC, 21 June 2024

As at the date of this announcement, the board of directors of the Company comprises Mr. Xiong Jun, Dr. Li Ning, Dr. Zou Jianjun, Mr. Li Cong, Mr. Zhang Zhuobing, Dr. Yao Sheng, Dr. Wang Gang and Dr. Li Xin as executive Directors; Mr. Tang Yi as non-executive Director; and Mr. Zhang Chun, Dr. Feng Xiaoyuan, Dr. Meng Anming, Dr. Shen Jing kang and Dr. Yang Yue as independent non-executive Directors.

* For identification purpose only

Shanghai Junshi Biosciences Co., Ltd.*
Announcement on Election of Chairman of the Board
of Directors, Vice Chairman of the Board of
Directors, Members of Special Committees under the
Board of Directors, Chairman of the Board of
Supervisors and Appointment of Senior Management
Personnel

The Board of Directors of the Company and all Directors warrant that there is no false and misleading statement or material omission herein, and shall undertake legal liabilities in accordance with the law for the truthfulness, accuracy and completeness of the contents herein.

In view of the upcoming expiry of the terms of the third session of the Board of Directors and the third session of the Board of Supervisors of Shanghai Junshi Biosciences Co., Ltd.* (hereinafter referred to as the “Company”), the Company convened the 2023 annual general meeting, 2024 first class meeting of A Shareholders and 2024 first class meeting of H Shareholders on 21 June 2024, at which the “Proposal on the Election of the Executive Directors and Non-executive Directors of the Fourth Session of the Board of Directors”, the “Proposal on the Election of the Independent Non-executive Directors of the Fourth Session of the Board of Directors” and the “Proposal on the Election of the Non-employee Representative Supervisor of the Fourth Session of the Board of Supervisors” have been considered and approved. The Company convened an employee representatives meeting on 20 June 2024 to consider and approve the “Proposal on the Election of the Employee Representative Supervisor

of the Fourth Session of the Board of Supervisors”. After the completion of the re-election and election of the Board of Directors and the Board of Supervisors at the general meetings, the Company convened the first meeting of the fourth session of the Board of Directors and the first meeting of the fourth session of the Board of Supervisors on the day of convening the general meeting, at which the “Proposal on the Election of Chairman and Vice Chairman of the Fourth Session of the Board of Directors of the Company”, “Proposal on the Election of Members and Chairman of Each Special Committee under the Fourth Session of the Board of Directors of the Company”, “Proposal on the Election of Chairman of the Fourth Session of the Board of Supervisors of the Company” and “Proposal on the Appointment of Senior Management Personnel of the Company” have been considered and approved. The particulars are hereby announced as follows:

I. Election of Chairman and Vice Chairman of the Fourth Session of the Board of Directors of the Company

In accordance with the Company Law of the People’s Republic of China (hereinafter referred to as the “Company Law”), the Articles of Association of Shanghai Junshi Biosciences Co., Ltd.* (hereinafter referred to as the “Articles of Association”) and other requirements, the Board of Directors of the Company elected Mr. Xiong Jun (熊俊) as the Chairman of the fourth session of the Board of Directors of the Company and Mr. NING LI (李寧) as the Vice Chairman of the fourth session of the Board of Directors of the Company, whose terms of office shall commence on the date of consideration and approval by the Board of Directors of the Company and end on the date of the expiration of the term of the fourth session of the Board of Directors of the Company.

For the biographical details of Mr. Xiong Jun and Mr. NING LI, please refer to the “Announcement on the Re-election and Election of the Board of Directors and the Board of Supervisors of Shanghai Junshi Biosciences Co., Ltd.*” (Announcement No.: Lin 2024-031) disclosed by the Company on the website of the Shanghai Stock Exchange (www.sse.com.cn) on 31 May 2024.

II. Election of Members and Chairman of Each Special Committee under the Fourth Session of the Board of Directors of the Company

In accordance with the Company Law, the Articles of Association and other requirements, the Board of Directors of the Company has elected the members and chairman of each Special Committee under the fourth session of the Board of Directors as follows:

- (1) The Audit Committee: Mr. Zhang Chun (張淳), Mr. Tang Yi (湯毅), Mr. Shen Jingkang (沈競康), of which Mr. Zhang Chun serves as the chairman;
- (2) The Nomination Committee: Mr. Feng Xiaoyuan (馮曉源), Mr. Xiong Jun, Ms. Yang Yue (楊悅), of which Mr. Feng Xiaoyuan serves as the chairman;
- (3) The Remuneration and Appraisal Committee: Mr. Zhang Chun, Mr. Xiong Jun, Ms. Zou Jianjun (鄒建軍), Mr. Feng Xiaoyuan, Ms. Yang Yue, of which Mr. Zhang Chun serves as the chairman;
- (4) The Strategic Committee: Mr. Xiong Jun, Ms. Zou Jianjun, Mr. Zhang Chun, Mr. Meng Anming (孟安明), Mr. Shen Jingkang, of which Mr. Xiong Jun serves as the chairman.

The independent non-executive directors account for more than half of each of the Audit Committee, the Nomination Committee and the Remuneration and Appraisal Committee of the Board of Directors and serve as the chairmen of these committees. Mr. Zhang Chun, the chairman of the Audit Committee, is an accounting professional. The term of office of Mr. Zhang Chun shall commence on the date of consideration and approval by the Board of Directors of the Company and expire on the date on which he has served as an independent non-executive Director of the Company for six consecutive years (i.e. 18 June 2026). The term of office of other Special Committee members under the fourth session of the Board of Directors of the Company shall commence on the date of consideration and approval by the Board of Directors of the Company and end on the date of the expiration of the term of the fourth session of the Board of Directors of the Company.

For the biographical details of the above-mentioned members, please refer to the

“Announcement on the Re-election and Election of the Board of Directors and the Board of Supervisors of Shanghai Junshi Biosciences Co., Ltd.*” (Announcement No.: Lin 2024-031) disclosed by the Company on the website of the Shanghai Stock Exchange (www.sse.com.cn) on 31 May 2024.

III. Election of Chairman of the Fourth Session of the Board of Supervisors of the Company

The Board of Supervisors of the Company has elected Ms. Kuang Hongyan (匡洪燕) as the Chairman of the fourth session of the Board of Supervisors of the Company, whose term of office shall commence on the date of consideration and approval by the Board of Supervisors of the Company and end on the date of the expiration of the term of the fourth session of the Board of Supervisors.

For the biographical details of Ms. Kuang Hongyan, please refer to the “Announcement on the Re-election and Election of the Board of Directors and the Board of Supervisors of Shanghai Junshi Biosciences Co., Ltd.*” (Announcement No.: Lin 2024-031) disclosed by the Company on the website of the Shanghai Stock Exchange (www.sse.com.cn) on 31 May 2024.

IV. Appointment of Senior Management Personnel

The Board of Directors of the Company agreed to appoint Ms. Zou Jianjun as the general manager and chief executive officer of the Company; Mr. Li Cong (李聰) as the co-chief executive officer of the Company; Mr. Zhang Zhuobing (張卓兵), Mr. SHENG YAO (姚盛) and Mr. GANG WANG (王剛) as the deputy general managers of the Company; Mr. Xu Baohong (許寶紅) as the financial director of the Company; and Mr. Wang Zhengyu (王征宇) as the secretary of the Board of Directors of the Company. The term of office of the aforesaid senior management personnel shall commence on the date of consideration and approval by the Board of Directors of the Company and end on the date of the expiration of the term of the fourth session of the Board of Directors of the Company.

The appointment of the above senior management personnel has been considered and approved by the Nomination Committee of the Company, and the appointment of the financial director of the Company has been considered and approved by the Audit

Committee of the Company. The above-mentioned senior management personnel have the qualifications appropriate to the exercise of their powers and their qualifications are in compliance with the Company Law, the Rules Governing the Listing of Stocks on the STAR Market of the Shanghai Stock Exchange (hereinafter referred to as the “STAR Market Listing Rules”) and other relevant laws, regulations and regulatory documents as well as relevant provisions of the Articles of Association, and there is no case of punishment by the China Securities Regulatory Commission or disciplinary action by the Shanghai Stock Exchange.

Mr. Wang Zhengyu, the secretary of the Board of Directors of the Company, has obtained the qualification certificate as a secretary of the board of directors issued by the STAR Market of the Shanghai Stock Exchange, and his qualifications are in compliance with the relevant requirements of the STAR Market Listing Rules.

Among the above personnel, the biographical details of Ms. Zou Jianjun, Mr. Li Cong, Mr. Zhang Zhuobing, Mr. SHENG YAO and Mr. GANG WANG are set out in the “Announcement on the Re-election and Election of the Board of Directors and the Board of Supervisors of Shanghai Junshi Biosciences Co., Ltd.*” (Announcement No.: Lin 2024-031) disclosed by the Company on the website of the Shanghai Stock Exchange (www.sse.com.cn) on 31 May 2024, and the biographies of Mr. Xu Baohong and Mr. Wang Zhengyu are detailed in the attachment.

V. Contact Details of the Secretary of the Board of Directors

Telephone: 021-61058800-1153

Fax: 021-61757377

E-mail: info@junshipharma.com

Office address: 15th Floor, Building 7, No. 6, Lane 100, Pingjiaqiao Road, Pudong New Area, Shanghai

Announcement is hereby given.

Shanghai Junshi Biosciences Co., Ltd. *

Board of Directors

22 June 2024

** For identification purpose only*

Attachment: Biographies

Mr. Xu Baohong (許寶紅), born in March 1979, with Chinese nationality without the right of permanent residence abroad, has served as the financial director of the Company since November 2020. Mr. Xu Baohong graduated from Shanghai University of Finance and Economics in 2004 and obtained a bachelor's degree in economics and a master's degree in management. His major work experiences include: from June 2004 to May 2011, he served as the head of treasury department of Shanghai Gas (Group) Co., Ltd. (上海燃氣(集團)有限公司); from May 2011 to April 2013, he served as the research director of Shanghai Homey Asset Management Co., Ltd. (上海宏銘投資管理有限公司); from April 2013 to February 2020, he served as the general manager and research director of Shanghai Shizhen Investment Management Centre (General Partnership) (上海世真投資管理中心(普通合夥)); from February 2020 to November 2020, he served as the head of strategic investment department of the Company; since February 2021, he has served as an executive director and the general manager of Junshi Biosciences (Hainan) Co., Ltd.; and since June 2021, he has served as an executive director and the general manager of Junshi Venture Capital (Hainan) Co., Ltd.

Mr. Wang Zhengyu (王征宇), born in April 1995, with Chinese nationality without the right of permanent residence abroad, has served as the secretary of the Board of the Company since April 2024. Mr. Wang Zhengyu obtained a master's degree in law from Tongji University and holds the national legal professional qualification and the qualification as a secretary of the board of directors from the STAR Market of the Shanghai Stock Exchange. Mr. Wang Zhengyu worked in the securities legal affairs department of Jiangsu Hengrui Medicine Co., Ltd. and served as a manager of the securities department of the Company from May 2019 to March 2021, and from March 2021 to April 2024, he served as a securities affairs representative of the Company.